

Global PET Diagnostic Radiopharmaceuticals Market Growth 2026-2032

<https://marketpublishers.com/r/G5A0D35CA436EN.html>

Date: October 2026

Pages: 136

Price: US\$ 3,660.00 (Single User License)

ID: G5A0D35CA436EN

Abstracts

The global PET Diagnostic Radiopharmaceuticals market size is predicted to grow from US\$ 5502 million in 2025 to US\$ 11208 million in 2032; it is expected to grow at a CAGR of 11.1% from 2026 to 2032.

PET Diagnostic Radiopharmaceuticals are radioactive diagnostic drugs designed for positron emission tomography imaging by incorporating positron-emitting radionuclides into biologically active molecules, metabolic substrates, receptor-binding ligands, or other molecular targeting compounds. After administration, these agents generate functional and molecular information according to their biodistribution, metabolism, receptor expression, protein deposition, or tissue perfusion and are used with PET, PET/CT, and PET/MR systems for disease detection, localization, staging, recurrence assessment, treatment planning, therapy response evaluation, and patient selection. The market is centered on fluorine-18, gallium-68, carbon-11, nitrogen-13, rubidium-82, and selected other positron-emitting radionuclides. Major commercial applications include oncology, neurology, and cardiology, covering glucose metabolism imaging, PSMA imaging, amyloid and tau imaging, somatostatin receptor imaging, and myocardial perfusion imaging. This study focuses on PET diagnostic radiopharmaceuticals supplied for human clinical use through regional radiopharmacies, cyclotron-based manufacturing networks, generator-based preparation systems, and qualified institutional production facilities.

Key Findings Fluorine-18-based PET radiopharmaceuticals remain the largest product category. Oncology remains the largest application segment, while PSMA PET is a key growth area. North America accounted for approximately 56.0% of the global market in 2025. Europe accounted for approximately 20.4% of the global market, while Asia Pacific represented about 18.7%. Market growth is increasingly shifting from traditional

FDG toward targeted imaging agents such as PSMA, amyloid beta, and tau PET tracers.

Market Trends

The PET diagnostic radiopharmaceutical industry is moving from predominantly metabolic imaging toward disease-specific molecular imaging. FDG remains fundamental to global PET utilization, but incremental value is increasingly generated by tracers that identify specific receptors, antigens, protein aggregates, or physiological processes. PSMA imaging has already established a strong commercial position in prostate cancer, while amyloid and tau imaging are expanding the role of PET in neurodegenerative disease assessment. Cardiac PET is also receiving renewed attention as newer F-18 myocardial perfusion approaches seek to overcome some of the logistical limitations associated with very short-lived tracers.

Another important trend is the closer integration of diagnostic PET with radioligand therapy. In prostate cancer, PET is increasingly embedded in patient-selection pathways for targeted radionuclide treatment. The FDA's July 2026 expansion of Pluvicto-related treatment use continues to require selection of PSMA-positive patients using Locametz or another approved PSMA PET product, reinforcing the strategic importance of diagnostic radiopharmaceuticals within theranostic workflows.

Market Dynamics

The market is characterized by a combination of pharmaceutical innovation and localized manufacturing economics. Unlike conventional pharmaceuticals, many PET radiopharmaceuticals cannot be manufactured at one global facility and shipped through normal pharmaceutical distribution channels. Half-life constraints create geographically fragmented production networks, especially for F-18, C-11, and N-13 products. Competitive advantage therefore depends not only on intellectual property and regulatory approval but also on cyclotron access, GMP radiopharmacy capacity, synthesis reliability, quality control, scheduling, and last-mile delivery.

At the same time, the economic center of the market is shifting toward targeted tracers with higher clinical differentiation. This transition improves the value generated per patient dose but also increases dependence on regulatory indications, reimbursement pathways, physician adoption, and companion therapeutic ecosystems. The result is a market in which mature FDG volumes provide a stable base while targeted products account for a rising proportion of incremental revenue.

Drivers

The primary growth driver is the increasing clinical adoption of molecular imaging in oncology. PSMA-targeted PET has materially improved the ability to detect PSMA-positive prostate cancer lesions and is now established in both initial staging and suspected recurrence settings. FDA approvals of Ga-68 and F-18 PSMA agents have progressively expanded commercial access to this imaging approach.

A second driver is the increasing connection between diagnostic imaging and precision treatment. PET tracers are becoming tools for determining whether patients express the molecular target required for specific radioligand therapies. In neurology, Alzheimer's disease diagnosis and treatment pathways are also creating demand for more precise assessment of amyloid pathology, although the competitive relationship between PET and emerging blood-based biomarkers will increasingly shape the addressable market.

Restraints

Production logistics remain one of the industry's most important structural restraints. The short half-lives of major PET radionuclides limit shipping distances and require dense manufacturing networks, reliable production scheduling, redundant cyclotron capacity, qualified personnel, and rapid quality-release procedures. This makes geographic market expansion more capital intensive than conventional pharmaceutical distribution and creates substantial differences in product availability between major metropolitan markets and lower-density regions.

The second restraint is reimbursement and clinical-economic justification. Targeted PET agents can create substantially greater clinical value than traditional imaging but generally require stronger evidence of diagnostic impact, treatment-selection utility, and health-economic benefit. Where reimbursement is limited, PET utilization can remain concentrated in tertiary hospitals and specialist imaging centers even after regulatory approval.

Opportunities

PSMA remains one of the clearest commercial opportunities because diagnostic PET is increasingly linked to both prostate cancer staging and targeted radioligand treatment pathways. The approval of additional PSMA PET products and generic versions is expanding supply while also validating the broader clinical category. In May 2026, the FDA listed the first generic approval for gallium Ga-68 gozetotide injection, indicating that the market is beginning to transition from early proprietary expansion toward a

broader competitive supply structure.

Neurology represents another significant opportunity, particularly where PET imaging is used to confirm amyloid or tau pathology and support therapeutic decision-making. However, this opportunity will evolve alongside lower-cost diagnostic alternatives. In May 2025, the FDA cleared the first blood-based in-vitro diagnostic test for Alzheimer's-related amyloid pathology and explicitly noted that such testing could reduce reliance on PET scans. PET is therefore likely to migrate toward higher-value confirmatory, treatment-selection, and complex diagnostic use rather than remain the only route to pathology assessment.

Challenges

The major strategic challenge is balancing innovation with manufacturing economics. A successful PET agent requires not only clinical differentiation and regulatory approval but also a production network capable of delivering reproducible doses within radionuclide half-life constraints. Technology transfer to regional radiopharmacies, validated synthesis processes, batch release, sterile manufacturing, radiation protection, and transportation must therefore scale in parallel with clinical adoption.

Substitution risk is also increasing in selected applications. Blood biomarkers may reduce some amyloid PET screening volumes, while improvements in MRI, CT, liquid biopsy, and other molecular diagnostics may affect selected diagnostic pathways. PET radiopharmaceuticals are most defensible where molecular imaging directly changes staging, treatment eligibility, or therapeutic selection rather than where the scan provides only incremental diagnostic information.

Industry Chain Analysis

The upstream industry includes enriched target materials, stable isotope precursors, radionuclide generators, cyclotron infrastructure, synthesis precursors, reagents, automated synthesis modules, sterile consumables, shielding systems, and quality-control equipment. Radionuclide production is particularly important because product economics and manufacturing geography differ substantially between cyclotron-produced isotopes such as F-18, C-11, and N-13 and generator-supported isotopes such as Ga-68 and Rb-82.

The midstream consists of radiopharmaceutical development, radionuclide labeling, GMP synthesis, sterile filling or patient-dose preparation, quality release, and time-

critical logistics. Downstream customers include hospitals, diagnostic imaging centers, and academic or research medical centers operating PET/CT or PET/MR systems. Because product half-life can determine the feasible distribution radius, the industry's physical manufacturing network is an integral part of the commercial value chain rather than a simple back-end production function.

Value Chain Analysis

Value capture varies materially by product type. Conventional FDG is a relatively mature, high-volume product in which manufacturing density, operational efficiency, route optimization, and customer coverage are critical. By contrast, targeted tracers such as PSMA, amyloid, tau, and SSTR products derive a larger share of their value from molecular specificity, clinical evidence, regulatory approval, intellectual property, and integration into specialty-care pathways.

As the product mix shifts toward targeted PET agents, commercial value increasingly moves toward companies capable of combining proprietary molecules with reliable regional manufacturing access. However, specialized radiopharmacy networks retain strong bargaining importance because the pharmaceutical innovator cannot monetize a short-lived PET tracer without geographically distributed manufacturing and delivery capability.

Segment Insights

By radionuclide, fluorine-18 remains the core commercial platform because its approximately 110-minute half-life provides a practical balance between centralized manufacturing, regional distribution, and imaging performance. The category spans FDG as well as a growing range of PSMA, amyloid, tau, estrogen receptor, amino-acid, and other targeted products. Gallium-68 is the other major targeted PET platform, particularly in PSMA and somatostatin receptor imaging, while carbon-11 and nitrogen-13 remain more closely tied to on-site or near-site cyclotron production.

By clinical application, oncology is the leading segment, followed by neurology and cardiology. From an imaging-target perspective, glucose metabolism remains the foundational volume category, while PSMA is one of the most important incremental revenue pools. Amyloid beta, tau protein, somatostatin receptors, and myocardial perfusion form additional commercially significant submarkets. Smaller and less standardized targets remain appropriately grouped within Others until their commercial adoption becomes sufficiently broad to support stable market segmentation.

Downstream Market Opportunities

Oncology offers the strongest near-term opportunity because PET is increasingly involved not only in lesion detection but also in staging, recurrence localization, biological characterization, and selection for targeted therapies. Prostate cancer is particularly important because PSMA PET can be used across several stages of the care pathway and directly links diagnostic imaging with radioligand therapy eligibility.

Neurology provides a second important growth area, but the opportunity is more differentiated. Amyloid and tau imaging can support more precise characterization of neurodegenerative disease, while emerging blood tests may reduce the need for PET in initial screening. This creates an opportunity for PET to move toward confirmatory diagnosis, ambiguous cases, treatment qualification, and advanced disease characterization rather than compete primarily as a mass-screening technology.

Regional Insights

North America remains the largest commercial market, supported by high PET/CT penetration, extensive commercial radiopharmacy coverage, rapid adoption of high-value PSMA imaging, and comparatively developed reimbursement pathways for advanced molecular imaging. The 2025 model indicates regional revenue of approximately US\$3.15 billion, representing about 56.0% of the commercial global market. The United States is also an important launch market for new PSMA, neurological, and cardiac PET products.

Europe represents approximately 20.4% of the 2025 market and has a more fragmented production structure, combining large multicountry radiopharmacy networks with national and regional manufacturers. Asia Pacific represents approximately 18.7% and has greater variation in market maturity. Japan has a long-established nuclear medicine infrastructure, while China is expanding both conventional PET production capacity and domestically developed targeted tracers. South Korea, Taiwan, Australia, and selected other markets also maintain specialized PET manufacturing capabilities, creating substantial room for regional expansion as advanced molecular imaging becomes more widely adopted.

Competitive Landscape Analysis

The competitive landscape is regionally fragmented because commercial success depends on both product ownership and geographic manufacturing coverage. North

America has the strongest concentration of large radiopharmacy networks and high-value proprietary tracers, creating a market in which nationwide manufacturing reach and specialty-product access reinforce each other. Europe has a more distributed competitive structure, with cross-border manufacturing networks coexisting with regional PET producers. Asia Pacific remains more locally structured, with national production systems playing a larger role because regulatory requirements, reimbursement, cyclotron availability, and delivery radius differ materially by market.

Competition is therefore developing along two parallel axes. One is molecular innovation, where differentiated PSMA, amyloid, tau, SSTR, and cardiac products compete on clinical utility and regulatory indications. The other is manufacturing reach, where companies compete through cyclotron density, radiopharmacy coverage, reliability, turnaround time, and delivery access. Over the medium term, companies that can combine differentiated PET assets with scalable regional production infrastructure are expected to occupy the strongest competitive positions.

Report Scope

LP Information, Inc. (LPI) ' newest research report, the “PET Diagnostic Radiopharmaceuticals Industry Forecast” looks at past sales and reviews total world PET Diagnostic Radiopharmaceuticals sales in 2025, providing a comprehensive analysis by region and market sector of projected PET Diagnostic Radiopharmaceuticals sales for 2026 through 2032. With PET Diagnostic Radiopharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world PET Diagnostic Radiopharmaceuticals industry.

This Insight Report provides a comprehensive analysis of the global PET Diagnostic Radiopharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PET Diagnostic Radiopharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global PET Diagnostic Radiopharmaceuticals market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PET Diagnostic Radiopharmaceuticals and breaks down the forecast by Radionuclide, by Application, geography, and market size to highlight

emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PET Diagnostic Radiopharmaceuticals.

This report presents a comprehensive overview, market shares, and growth opportunities of PET Diagnostic Radiopharmaceuticals market by product type, application, key manufacturers and key regions and countries.

Market Segmentation

Segmentation by Radionuclide:

Fluorine 18 Based Radiopharmaceuticals

Gallium 68 Based Radiopharmaceuticals

Carbon 11 Based Radiopharmaceuticals

Nitrogen 13 Based Radiopharmaceuticals

Rubidium 82 Based Radiopharmaceuticals

Others

Segmentation by Molecular Imaging Mechanism:

Metabolic Imaging

Receptor and Antigen Targeted Imaging

Protein Aggregate Imaging

Perfusion and Functional Imaging

Others

Segmentation by Imaging Target:

Glucose Metabolism

Prostate Specific Membrane Antigen

Amyloid Beta

Tau Protein

Somatostatin Receptor

Myocardial Perfusion

Others

Segmentation by Application:

Oncology

Neurology

Cardiology

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Siemens Healthineers AG

Curium

Cardinal Health, Inc.

GE HealthCare Technologies Inc.

SOFIE Biosciences, Inc.

China Isotope & Radiation Corporation

Beijing Sinotau International Pharmaceutical Technology Co., Ltd.

Cyclotek Pty Ltd

BIONT, a.s.

FutureChem Co., Ltd.

Top Radiopharmaceuticals Co., Ltd.

Asia Allied Infrastructure Holdings Limited

Global Medical Solutions

BIOKOSMOS

SYN Innovation Laboratories S.A.

Board of Radiation & Isotope Technology

SDS Life Sciences Pvt. Ltd.

Molecular Cyclotrons Pvt. Ltd.

VRM Molecular & Nuclear Medicines Pvt. Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global PET Diagnostic Radiopharmaceuticals market?

What factors are driving PET Diagnostic Radiopharmaceuticals market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do PET Diagnostic Radiopharmaceuticals market opportunities vary by end market size?

How does PET Diagnostic Radiopharmaceuticals break out by Radionuclide, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global PET Diagnostic Radiopharmaceuticals Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for PET Diagnostic Radiopharmaceuticals by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for PET Diagnostic Radiopharmaceuticals by Country/Region, 2021, 2025 & 2032

2.2 PET Diagnostic Radiopharmaceuticals Segment by Radionuclide

- 2.2.1 Fluorine 18 Based Radiopharmaceuticals
- 2.2.2 Gallium 68 Based Radiopharmaceuticals
- 2.2.3 Carbon 11 Based Radiopharmaceuticals
- 2.2.4 Nitrogen 13 Based Radiopharmaceuticals
- 2.2.5 Rubidium 82 Based Radiopharmaceuticals
- 2.2.6 Others
- 2.2.7 PET Diagnostic Radiopharmaceuticals Sales by Radionuclide
 - 2.2.7.1 Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Radionuclide (2021-2026)
 - 2.2.7.2 Global PET Diagnostic Radiopharmaceuticals Revenue and Market Share by Radionuclide (2021-2026)
 - 2.2.7.3 Global PET Diagnostic Radiopharmaceuticals Sale Price by Radionuclide (2021-2026)

2.3 PET Diagnostic Radiopharmaceuticals Segment by Molecular Imaging Mechanism

- 2.3.1 Metabolic Imaging
- 2.3.2 Receptor and Antigen Targeted Imaging
- 2.3.3 Protein Aggregate Imaging

2.3.4 Perfusion and Functional Imaging

2.3.5 Others

2.3.6 PET Diagnostic Radiopharmaceuticals Sales by Molecular Imaging Mechanism

2.3.6.1 Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Molecular Imaging Mechanism (2021-2026)

2.3.6.2 Global PET Diagnostic Radiopharmaceuticals Revenue and Market Share by Molecular Imaging Mechanism (2021-2026)

2.3.6.3 Global PET Diagnostic Radiopharmaceuticals Sale Price by Molecular Imaging Mechanism (2021-2026)

2.4 PET Diagnostic Radiopharmaceuticals Segment by Imaging Target

2.4.1 Glucose Metabolism

2.4.2 Prostate Specific Membrane Antigen

2.4.3 Amyloid Beta

2.4.4 Tau Protein

2.4.5 Somatostatin Receptor

2.4.6 Myocardial Perfusion

2.4.7 Others

2.4.8 PET Diagnostic Radiopharmaceuticals Sales by Imaging Target

2.4.8.1 Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Imaging Target (2021-2026)

2.4.8.2 Global PET Diagnostic Radiopharmaceuticals Revenue and Market Share by Imaging Target (2021-2026)

2.4.8.3 Global PET Diagnostic Radiopharmaceuticals Sale Price by Imaging Target (2021-2026)

2.5 PET Diagnostic Radiopharmaceuticals Segment by Application

2.5.1 Oncology

2.5.2 Neurology

2.5.3 Cardiology

2.5.4 Others

2.5.5 PET Diagnostic Radiopharmaceuticals Sales by Application

2.5.5.1 Global PET Diagnostic Radiopharmaceuticals Sale Market Share by Application (2021-2026)

2.5.5.2 Global PET Diagnostic Radiopharmaceuticals Revenue and Market Share by Application (2021-2026)

2.5.5.3 Global PET Diagnostic Radiopharmaceuticals Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global PET Diagnostic Radiopharmaceuticals Breakdown Data by Company

3.1.1 Global PET Diagnostic Radiopharmaceuticals Annual Sales by Company (2021-2026)

3.1.2 Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Company (2021-2026)

3.2 Global PET Diagnostic Radiopharmaceuticals Annual Revenue by Company (2021-2026)

3.2.1 Global PET Diagnostic Radiopharmaceuticals Revenue by Company (2021-2026)

3.2.2 Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Company (2021-2026)

3.3 Global PET Diagnostic Radiopharmaceuticals Sale Price by Company

3.4 Key Manufacturers PET Diagnostic Radiopharmaceuticals Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers PET Diagnostic Radiopharmaceuticals Product Location Distribution

3.4.2 Players PET Diagnostic Radiopharmaceuticals Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR PET DIAGNOSTIC RADIOPHARMACEUTICALS BY GEOGRAPHIC REGION

4.1 World Historic PET Diagnostic Radiopharmaceuticals Market Size by Geographic Region (2021-2026)

4.1.1 Global PET Diagnostic Radiopharmaceuticals Annual Sales by Geographic Region (2021-2026)

4.1.2 Global PET Diagnostic Radiopharmaceuticals Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic PET Diagnostic Radiopharmaceuticals Market Size by Country/Region (2021-2026)

4.2.1 Global PET Diagnostic Radiopharmaceuticals Annual Sales by Country/Region (2021-2026)

4.2.2 Global PET Diagnostic Radiopharmaceuticals Annual Revenue by Country/Region (2021-2026)

4.3 Americas PET Diagnostic Radiopharmaceuticals Sales Growth

- 4.4 APAC PET Diagnostic Radiopharmaceuticals Sales Growth
- 4.5 Europe PET Diagnostic Radiopharmaceuticals Sales Growth
- 4.6 Middle East & Africa PET Diagnostic Radiopharmaceuticals Sales Growth

5 AMERICAS

- 5.1 Americas PET Diagnostic Radiopharmaceuticals Sales by Country
 - 5.1.1 Americas PET Diagnostic Radiopharmaceuticals Sales by Country (2021-2026)
 - 5.1.2 Americas PET Diagnostic Radiopharmaceuticals Revenue by Country (2021-2026)
- 5.2 Americas PET Diagnostic Radiopharmaceuticals Sales by Radionuclide (2021-2026)
- 5.3 Americas PET Diagnostic Radiopharmaceuticals Sales by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC PET Diagnostic Radiopharmaceuticals Sales by Region
 - 6.1.1 APAC PET Diagnostic Radiopharmaceuticals Sales by Region (2021-2026)
 - 6.1.2 APAC PET Diagnostic Radiopharmaceuticals Revenue by Region (2021-2026)
- 6.2 APAC PET Diagnostic Radiopharmaceuticals Sales by Radionuclide (2021-2026)
- 6.3 APAC PET Diagnostic Radiopharmaceuticals Sales by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe PET Diagnostic Radiopharmaceuticals by Country
 - 7.1.1 Europe PET Diagnostic Radiopharmaceuticals Sales by Country (2021-2026)
 - 7.1.2 Europe PET Diagnostic Radiopharmaceuticals Revenue by Country (2021-2026)
- 7.2 Europe PET Diagnostic Radiopharmaceuticals Sales by Radionuclide (2021-2026)

7.3 Europe PET Diagnostic Radiopharmaceuticals Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa PET Diagnostic Radiopharmaceuticals by Country

8.1.1 Middle East & Africa PET Diagnostic Radiopharmaceuticals Sales by Country (2021-2026)

8.1.2 Middle East & Africa PET Diagnostic Radiopharmaceuticals Revenue by Country (2021-2026)

8.2 Middle East & Africa PET Diagnostic Radiopharmaceuticals Sales by Radionuclide (2021-2026)

8.3 Middle East & Africa PET Diagnostic Radiopharmaceuticals Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of PET Diagnostic Radiopharmaceuticals

10.3 Manufacturing Process Analysis of PET Diagnostic Radiopharmaceuticals

10.4 Industry Chain Structure of PET Diagnostic Radiopharmaceuticals

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 PET Diagnostic Radiopharmaceuticals Distributors

11.3 PET Diagnostic Radiopharmaceuticals Customer

12 WORLD FORECAST REVIEW FOR PET DIAGNOSTIC RADIOPHARMACEUTICALS BY GEOGRAPHIC REGION

12.1 Global PET Diagnostic Radiopharmaceuticals Market Size Forecast by Region

12.1.1 Global PET Diagnostic Radiopharmaceuticals Forecast by Region (2027-2032)

12.1.2 Global PET Diagnostic Radiopharmaceuticals Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global PET Diagnostic Radiopharmaceuticals Forecast by Radionuclide (2027-2032)

12.7 Global PET Diagnostic Radiopharmaceuticals Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Siemens Healthineers AG

13.1.1 Siemens Healthineers AG Company Information

13.1.2 Siemens Healthineers AG PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.1.3 Siemens Healthineers AG PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Siemens Healthineers AG Main Business Overview

13.1.5 Siemens Healthineers AG Latest Developments

13.2 Curium

13.2.1 Curium Company Information

13.2.2 Curium PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.2.3 Curium PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Curium Main Business Overview

13.2.5 Curium Latest Developments

13.3 Cardinal Health, Inc.

13.3.1 Cardinal Health, Inc. Company Information

13.3.2 Cardinal Health, Inc. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.3.3 Cardinal Health, Inc. PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Cardinal Health, Inc. Main Business Overview

13.3.5 Cardinal Health, Inc. Latest Developments

13.4 GE HealthCare Technologies Inc.

13.4.1 GE HealthCare Technologies Inc. Company Information

13.4.2 GE HealthCare Technologies Inc. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.4.3 GE HealthCare Technologies Inc. PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 GE HealthCare Technologies Inc. Main Business Overview

13.4.5 GE HealthCare Technologies Inc. Latest Developments

13.5 SOFIE Biosciences, Inc.

13.5.1 SOFIE Biosciences, Inc. Company Information

13.5.2 SOFIE Biosciences, Inc. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.5.3 SOFIE Biosciences, Inc. PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 SOFIE Biosciences, Inc. Main Business Overview

13.5.5 SOFIE Biosciences, Inc. Latest Developments

13.6 China Isotope & Radiation Corporation

13.6.1 China Isotope & Radiation Corporation Company Information

13.6.2 China Isotope & Radiation Corporation PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.6.3 China Isotope & Radiation Corporation PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 China Isotope & Radiation Corporation Main Business Overview

13.6.5 China Isotope & Radiation Corporation Latest Developments

13.7 Beijing Sinotau International Pharmaceutical Technology Co., Ltd.

13.7.1 Beijing Sinotau International Pharmaceutical Technology Co., Ltd. Company Information

13.7.2 Beijing Sinotau International Pharmaceutical Technology Co., Ltd. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.7.3 Beijing Sinotau International Pharmaceutical Technology Co., Ltd. PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Beijing Sinotau International Pharmaceutical Technology Co., Ltd. Main Business Overview

13.7.5 Beijing Sinotau International Pharmaceutical Technology Co., Ltd. Latest Developments

13.8 Cyclotek Pty Ltd

13.8.1 Cyclotek Pty Ltd Company Information

13.8.2 Cyclotek Pty Ltd PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.8.3 Cyclotek Pty Ltd PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Cyclotek Pty Ltd Main Business Overview

13.8.5 Cyclotek Pty Ltd Latest Developments

13.9 BIONT, a.s.

13.9.1 BIONT, a.s. Company Information

13.9.2 BIONT, a.s. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.9.3 BIONT, a.s. PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 BIONT, a.s. Main Business Overview

13.9.5 BIONT, a.s. Latest Developments

13.10 FutureChem Co., Ltd.

13.10.1 FutureChem Co., Ltd. Company Information

13.10.2 FutureChem Co., Ltd. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.10.3 FutureChem Co., Ltd. PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 FutureChem Co., Ltd. Main Business Overview

13.10.5 FutureChem Co., Ltd. Latest Developments

13.11 Top Radiopharmaceuticals Co., Ltd.

13.11.1 Top Radiopharmaceuticals Co., Ltd. Company Information

13.11.2 Top Radiopharmaceuticals Co., Ltd. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.11.3 Top Radiopharmaceuticals Co., Ltd. PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Top Radiopharmaceuticals Co., Ltd. Main Business Overview

13.11.5 Top Radiopharmaceuticals Co., Ltd. Latest Developments

13.12 Asia Allied Infrastructure Holdings Limited

13.12.1 Asia Allied Infrastructure Holdings Limited Company Information

13.12.2 Asia Allied Infrastructure Holdings Limited PET Diagnostic

Radiopharmaceuticals Product Portfolios and Specifications

13.12.3 Asia Allied Infrastructure Holdings Limited PET Diagnostic

Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Asia Allied Infrastructure Holdings Limited Main Business Overview

13.12.5 Asia Allied Infrastructure Holdings Limited Latest Developments

13.13 Global Medical Solutions

13.13.1 Global Medical Solutions Company Information

13.13.2 Global Medical Solutions PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.13.3 Global Medical Solutions PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Global Medical Solutions Main Business Overview

13.13.5 Global Medical Solutions Latest Developments

13.14 BOKOSMOS

13.14.1 BOKOSMOS Company Information

13.14.2 BOKOSMOS PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.14.3 BOKOSMOS PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.14.4 BOKOSMOS Main Business Overview

13.14.5 BOKOSMOS Latest Developments

13.15 SYN Innovation Laboratories S.A.

13.15.1 SYN Innovation Laboratories S.A. Company Information

13.15.2 SYN Innovation Laboratories S.A. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.15.3 SYN Innovation Laboratories S.A. PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.15.4 SYN Innovation Laboratories S.A. Main Business Overview

13.15.5 SYN Innovation Laboratories S.A. Latest Developments

13.16 Board of Radiation & Isotope Technology

13.16.1 Board of Radiation & Isotope Technology Company Information

13.16.2 Board of Radiation & Isotope Technology PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.16.3 Board of Radiation & Isotope Technology PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.16.4 Board of Radiation & Isotope Technology Main Business Overview

13.16.5 Board of Radiation & Isotope Technology Latest Developments

13.17 SDS Life Sciences Pvt. Ltd.

13.17.1 SDS Life Sciences Pvt. Ltd. Company Information

13.17.2 SDS Life Sciences Pvt. Ltd. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.17.3 SDS Life Sciences Pvt. Ltd. PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.17.4 SDS Life Sciences Pvt. Ltd. Main Business Overview

13.17.5 SDS Life Sciences Pvt. Ltd. Latest Developments

13.18 Molecular Cyclotrons Pvt. Ltd.

13.18.1 Molecular Cyclotrons Pvt. Ltd. Company Information

13.18.2 Molecular Cyclotrons Pvt. Ltd. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.18.3 Molecular Cyclotrons Pvt. Ltd. PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.18.4 Molecular Cyclotrons Pvt. Ltd. Main Business Overview

13.18.5 Molecular Cyclotrons Pvt. Ltd. Latest Developments

13.19 VRM Molecular & Nuclear Medicines Pvt. Ltd.

13.19.1 VRM Molecular & Nuclear Medicines Pvt. Ltd. Company Information

13.19.2 VRM Molecular & Nuclear Medicines Pvt. Ltd. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

13.19.3 VRM Molecular & Nuclear Medicines Pvt. Ltd. PET Diagnostic Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)

13.19.4 VRM Molecular & Nuclear Medicines Pvt. Ltd. Main Business Overview

13.19.5 VRM Molecular & Nuclear Medicines Pvt. Ltd. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. PET Diagnostic Radiopharmaceuticals Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. PET Diagnostic Radiopharmaceuticals Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Fluorine 18 Based Radiopharmaceuticals

Table 4. Major Players of Gallium 68 Based Radiopharmaceuticals

Table 5. Major Players of Carbon 11 Based Radiopharmaceuticals

Table 6. Major Players of Nitrogen 13 Based Radiopharmaceuticals

Table 7. Major Players of Rubidium 82 Based Radiopharmaceuticals

Table 8. Major Players of Others

Table 9. Global PET Diagnostic Radiopharmaceuticals Sales by Radionuclide (2021-2026) & (K Dose)

Table 10. Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Radionuclide (2021-2026)

Table 11. Global PET Diagnostic Radiopharmaceuticals Revenue by Radionuclide (2021-2026) & (\$ million)

Table 12. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Radionuclide (2021-2026)

Table 13. Global PET Diagnostic Radiopharmaceuticals Sale Price by Radionuclide (2021-2026) & (US\$/Dose)

Table 14. Major Players of Metabolic Imaging

Table 15. Major Players of Receptor and Antigen Targeted Imaging

Table 16. Major Players of Protein Aggregate Imaging

Table 17. Major Players of Perfusion and Functional Imaging

Table 18. Major Players of Others

Table 19. Global PET Diagnostic Radiopharmaceuticals Sales by Molecular Imaging Mechanism (2021-2026) & (K Dose)

Table 20. Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Molecular Imaging Mechanism (2021-2026)

Table 21. Global PET Diagnostic Radiopharmaceuticals Revenue by Molecular Imaging Mechanism (2021-2026) & (\$ million)

Table 22. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Molecular Imaging Mechanism (2021-2026)

Table 23. Global PET Diagnostic Radiopharmaceuticals Sale Price by Molecular Imaging Mechanism (2021-2026) & (US\$/Dose)

Table 24. Major Players of Glucose Metabolism
Table 25. Major Players of Prostate Specific Membrane Antigen
Table 26. Major Players of Amyloid Beta
Table 27. Major Players of Tau Protein
Table 28. Major Players of Somatostatin Receptor
Table 29. Major Players of Myocardial Perfusion
Table 30. Major Players of Others
Table 31. Global PET Diagnostic Radiopharmaceuticals Sales by Imaging Target (2021-2026) & (K Dose)
Table 32. Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Imaging Target (2021-2026)
Table 33. Global PET Diagnostic Radiopharmaceuticals Revenue by Imaging Target (2021-2026) & (\$ million)
Table 34. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Imaging Target (2021-2026)
Table 35. Global PET Diagnostic Radiopharmaceuticals Sale Price by Imaging Target (2021-2026) & (US\$/Dose)
Table 36. Global PET Diagnostic Radiopharmaceuticals Sale by Application (2021-2026) & (K Dose)
Table 37. Global PET Diagnostic Radiopharmaceuticals Sale Market Share by Application (2021-2026)
Table 38. Global PET Diagnostic Radiopharmaceuticals Revenue by Application (2021-2026) & (\$ million)
Table 39. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Application (2021-2026)
Table 40. Global PET Diagnostic Radiopharmaceuticals Sale Price by Application (2021-2026) & (US\$/Dose)
Table 41. Global PET Diagnostic Radiopharmaceuticals Sales by Company (2021-2026) & (K Dose)
Table 42. Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Company (2021-2026)
Table 43. Global PET Diagnostic Radiopharmaceuticals Revenue by Company (2021-2026) & (\$ millions)
Table 44. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Company (2021-2026)
Table 45. Global PET Diagnostic Radiopharmaceuticals Sale Price by Company (2021-2026) & (US\$/Dose)
Table 46. Key Manufacturers PET Diagnostic Radiopharmaceuticals Producing Area Distribution and Sales Area

Table 47. Players PET Diagnostic Radiopharmaceuticals Products Offered
Table 48. PET Diagnostic Radiopharmaceuticals Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 49. New Products and Potential Entrants
Table 50. Market M&A Activity & Strategy
Table 51. Global PET Diagnostic Radiopharmaceuticals Sales by Geographic Region (2021-2026) & (K Dose)
Table 52. Global PET Diagnostic Radiopharmaceuticals Sales Market Share Geographic Region (2021-2026)
Table 53. Global PET Diagnostic Radiopharmaceuticals Revenue by Geographic Region (2021-2026) & (\$ millions)
Table 54. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Geographic Region (2021-2026)
Table 55. Global PET Diagnostic Radiopharmaceuticals Sales by Country/Region (2021-2026) & (K Dose)
Table 56. Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Country/Region (2021-2026)
Table 57. Global PET Diagnostic Radiopharmaceuticals Revenue by Country/Region (2021-2026) & (\$ millions)
Table 58. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Country/Region (2021-2026)
Table 59. Americas PET Diagnostic Radiopharmaceuticals Sales by Country (2021-2026) & (K Dose)
Table 60. Americas PET Diagnostic Radiopharmaceuticals Sales Market Share by Country (2021-2026)
Table 61. Americas PET Diagnostic Radiopharmaceuticals Revenue by Country (2021-2026) & (\$ millions)
Table 62. Americas PET Diagnostic Radiopharmaceuticals Sales by Radionuclide (2021-2026) & (K Dose)
Table 63. Americas PET Diagnostic Radiopharmaceuticals Sales by Application (2021-2026) & (K Dose)
Table 64. APAC PET Diagnostic Radiopharmaceuticals Sales by Region (2021-2026) & (K Dose)
Table 65. APAC PET Diagnostic Radiopharmaceuticals Sales Market Share by Region (2021-2026)
Table 66. APAC PET Diagnostic Radiopharmaceuticals Revenue by Region (2021-2026) & (\$ millions)
Table 67. APAC PET Diagnostic Radiopharmaceuticals Sales by Radionuclide (2021-2026) & (K Dose)

Table 68. APAC PET Diagnostic Radiopharmaceuticals Sales by Application (2021-2026) & (K Dose)
Table 69. Europe PET Diagnostic Radiopharmaceuticals Sales by Country (2021-2026) & (K Dose)
Table 70. Europe PET Diagnostic Radiopharmaceuticals Revenue by Country (2021-2026) & (\$ millions)
Table 71. Europe PET Diagnostic Radiopharmaceuticals Sales by Radionuclide (2021-2026) & (K Dose)
Table 72. Europe PET Diagnostic Radiopharmaceuticals Sales by Application (2021-2026) & (K Dose)
Table 73. Middle East & Africa PET Diagnostic Radiopharmaceuticals Sales by Country (2021-2026) & (K Dose)
Table 74. Middle East & Africa PET Diagnostic Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Table 75. Middle East & Africa PET Diagnostic Radiopharmaceuticals Sales by Radionuclide (2021-2026) & (K Dose)
Table 76. Middle East & Africa PET Diagnostic Radiopharmaceuticals Sales by Application (2021-2026) & (K Dose)
Table 77. Key Market Drivers & Growth Opportunities of PET Diagnostic Radiopharmaceuticals
Table 78. Key Market Challenges & Risks of PET Diagnostic Radiopharmaceuticals
Table 79. Key Industry Trends of PET Diagnostic Radiopharmaceuticals
Table 80. PET Diagnostic Radiopharmaceuticals Raw Material
Table 81. Key Suppliers of Raw Materials
Table 82. PET Diagnostic Radiopharmaceuticals Distributors List
Table 83. PET Diagnostic Radiopharmaceuticals Customer List
Table 84. Global PET Diagnostic Radiopharmaceuticals Sales Forecast by Region (2027-2032) & (K Dose)
Table 85. Global PET Diagnostic Radiopharmaceuticals Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 86. Americas PET Diagnostic Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (K Dose)
Table 87. Americas PET Diagnostic Radiopharmaceuticals Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 88. APAC PET Diagnostic Radiopharmaceuticals Sales Forecast by Region (2027-2032) & (K Dose)
Table 89. APAC PET Diagnostic Radiopharmaceuticals Annual Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 90. Europe PET Diagnostic Radiopharmaceuticals Sales Forecast by Country

(2027-2032) & (K Dose)

Table 91. Europe PET Diagnostic Radiopharmaceuticals Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 92. Middle East & Africa PET Diagnostic Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (K Dose)

Table 93. Middle East & Africa PET Diagnostic Radiopharmaceuticals Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 94. Global PET Diagnostic Radiopharmaceuticals Sales Forecast by Radionuclide (2027-2032) & (K Dose)

Table 95. Global PET Diagnostic Radiopharmaceuticals Revenue Forecast by Radionuclide (2027-2032) & (\$ millions)

Table 96. Global PET Diagnostic Radiopharmaceuticals Sales Forecast by Application (2027-2032) & (K Dose)

Table 97. Global PET Diagnostic Radiopharmaceuticals Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 98. Siemens Healthineers AG Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors

Table 99. Siemens Healthineers AG PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

Table 100. Siemens Healthineers AG PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 101. Siemens Healthineers AG Main Business

Table 102. Siemens Healthineers AG Latest Developments

Table 103. Curium Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors

Table 104. Curium PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

Table 105. Curium PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 106. Curium Main Business

Table 107. Curium Latest Developments

Table 108. Cardinal Health, Inc. Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors

Table 109. Cardinal Health, Inc. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

Table 110. Cardinal Health, Inc. PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 111. Cardinal Health, Inc. Main Business

Table 112. Cardinal Health, Inc. Latest Developments

Table 113. GE HealthCare Technologies Inc. Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors

Table 114. GE HealthCare Technologies Inc. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

Table 115. GE HealthCare Technologies Inc. PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 116. GE HealthCare Technologies Inc. Main Business

Table 117. GE HealthCare Technologies Inc. Latest Developments

Table 118. SOFIE Biosciences, Inc. Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors

Table 119. SOFIE Biosciences, Inc. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

Table 120. SOFIE Biosciences, Inc. PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 121. SOFIE Biosciences, Inc. Main Business

Table 122. SOFIE Biosciences, Inc. Latest Developments

Table 123. China Isotope & Radiation Corporation Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors

Table 124. China Isotope & Radiation Corporation PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

Table 125. China Isotope & Radiation Corporation PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 126. China Isotope & Radiation Corporation Main Business

Table 127. China Isotope & Radiation Corporation Latest Developments

Table 128. Beijing Sinotau International Pharmaceutical Technology Co., Ltd. Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors

Table 129. Beijing Sinotau International Pharmaceutical Technology Co., Ltd. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

Table 130. Beijing Sinotau International Pharmaceutical Technology Co., Ltd. PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 131. Beijing Sinotau International Pharmaceutical Technology Co., Ltd. Main Business

Table 132. Beijing Sinotau International Pharmaceutical Technology Co., Ltd. Latest Developments

Table 133. Cyclotek Pty Ltd Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors

Table 134. Cyclotek Pty Ltd PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

Table 135. Cyclotek Pty Ltd PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 136. Cyclotek Pty Ltd Main Business

Table 137. Cyclotek Pty Ltd Latest Developments

Table 138. BIONT, a.s. Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors

Table 139. BIONT, a.s. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

Table 140. BIONT, a.s. PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 141. BIONT, a.s. Main Business

Table 142. BIONT, a.s. Latest Developments

Table 143. FutureChem Co., Ltd. Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors

Table 144. FutureChem Co., Ltd. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

Table 145. FutureChem Co., Ltd. PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 146. FutureChem Co., Ltd. Main Business

Table 147. FutureChem Co., Ltd. Latest Developments

Table 148. Top Radiopharmaceuticals Co., Ltd. Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors

Table 149. Top Radiopharmaceuticals Co., Ltd. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

Table 150. Top Radiopharmaceuticals Co., Ltd. PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 151. Top Radiopharmaceuticals Co., Ltd. Main Business

Table 152. Top Radiopharmaceuticals Co., Ltd. Latest Developments

Table 153. Asia Allied Infrastructure Holdings Limited Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors

Table 154. Asia Allied Infrastructure Holdings Limited PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications

Table 155. Asia Allied Infrastructure Holdings Limited PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 156. Asia Allied Infrastructure Holdings Limited Main Business

Table 157. Asia Allied Infrastructure Holdings Limited Latest Developments

Table 158. Global Medical Solutions Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 159. Global Medical Solutions PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications
Table 160. Global Medical Solutions PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 161. Global Medical Solutions Main Business
Table 162. Global Medical Solutions Latest Developments
Table 163. BOKOSMOS Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 164. BOKOSMOS PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications
Table 165. BOKOSMOS PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 166. BOKOSMOS Main Business
Table 167. BOKOSMOS Latest Developments
Table 168. SYN Innovation Laboratories S.A. Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 169. SYN Innovation Laboratories S.A. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications
Table 170. SYN Innovation Laboratories S.A. PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 171. SYN Innovation Laboratories S.A. Main Business
Table 172. SYN Innovation Laboratories S.A. Latest Developments
Table 173. Board of Radiation & Isotope Technology Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 174. Board of Radiation & Isotope Technology PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications
Table 175. Board of Radiation & Isotope Technology PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 176. Board of Radiation & Isotope Technology Main Business
Table 177. Board of Radiation & Isotope Technology Latest Developments
Table 178. SDS Life Sciences Pvt. Ltd. Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 179. SDS Life Sciences Pvt. Ltd. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications
Table 180. SDS Life Sciences Pvt. Ltd. PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 181. SDS Life Sciences Pvt. Ltd. Main Business
Table 182. SDS Life Sciences Pvt. Ltd. Latest Developments
Table 183. Molecular Cyclotrons Pvt. Ltd. Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 184. Molecular Cyclotrons Pvt. Ltd. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications
Table 185. Molecular Cyclotrons Pvt. Ltd. PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 186. Molecular Cyclotrons Pvt. Ltd. Main Business
Table 187. Molecular Cyclotrons Pvt. Ltd. Latest Developments
Table 188. VRM Molecular & Nuclear Medicines Pvt. Ltd. Basic Information, PET Diagnostic Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 189. VRM Molecular & Nuclear Medicines Pvt. Ltd. PET Diagnostic Radiopharmaceuticals Product Portfolios and Specifications
Table 190. VRM Molecular & Nuclear Medicines Pvt. Ltd. PET Diagnostic Radiopharmaceuticals Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 191. VRM Molecular & Nuclear Medicines Pvt. Ltd. Main Business
Table 192. VRM Molecular & Nuclear Medicines Pvt. Ltd. Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of PET Diagnostic Radiopharmaceuticals
- Figure 2. PET Diagnostic Radiopharmaceuticals Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global PET Diagnostic Radiopharmaceuticals Sales Growth Rate 2021-2032 (K Dose)
- Figure 7. Global PET Diagnostic Radiopharmaceuticals Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. PET Diagnostic Radiopharmaceuticals Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. PET Diagnostic Radiopharmaceuticals Sales Market Share by Country/Region (2025)
- Figure 10. PET Diagnostic Radiopharmaceuticals Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Fluorine 18 Based Radiopharmaceuticals
- Figure 12. Product Picture of Gallium 68 Based Radiopharmaceuticals
- Figure 13. Product Picture of Carbon 11 Based Radiopharmaceuticals
- Figure 14. Product Picture of Nitrogen 13 Based Radiopharmaceuticals
- Figure 15. Product Picture of Rubidium 82 Based Radiopharmaceuticals
- Figure 16. Product Picture of Others
- Figure 17. Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Radionuclide in 2026
- Figure 18. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Radionuclide (2021-2026)
- Figure 19. Product Picture of Metabolic Imaging
- Figure 20. Product Picture of Receptor and Antigen Targeted Imaging
- Figure 21. Product Picture of Protein Aggregate Imaging
- Figure 22. Product Picture of Perfusion and Functional Imaging
- Figure 23. Product Picture of Others
- Figure 24. Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Molecular Imaging Mechanism in 2026
- Figure 25. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Molecular Imaging Mechanism (2021-2026)
- Figure 26. Product Picture of Glucose Metabolism

Figure 27. Product Picture of Prostate Specific Membrane Antigen

Figure 28. Product Picture of Amyloid Beta

Figure 29. Product Picture of Tau Protein

Figure 30. Product Picture of Somatostatin Receptor

Figure 31. Product Picture of Myocardial Perfusion

Figure 32. Product Picture of Others

Figure 33. Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Imaging Target in 2026

Figure 34. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Imaging Target (2021-2026)

Figure 35. PET Diagnostic Radiopharmaceuticals Consumed in Oncology

Figure 36. Global PET Diagnostic Radiopharmaceuticals Market: Oncology (2021-2026) & (K Dose)

Figure 37. PET Diagnostic Radiopharmaceuticals Consumed in Neurology

Figure 38. Global PET Diagnostic Radiopharmaceuticals Market: Neurology (2021-2026) & (K Dose)

Figure 39. PET Diagnostic Radiopharmaceuticals Consumed in Cardiology

Figure 40. Global PET Diagnostic Radiopharmaceuticals Market: Cardiology (2021-2026) & (K Dose)

Figure 41. PET Diagnostic Radiopharmaceuticals Consumed in Others

Figure 42. Global PET Diagnostic Radiopharmaceuticals Market: Others (2021-2026) & (K Dose)

Figure 43. Global PET Diagnostic Radiopharmaceuticals Sale Market Share by Application (2025)

Figure 44. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Application in 2025

Figure 45. PET Diagnostic Radiopharmaceuticals Sales by Company in 2025 (K Dose)

Figure 46. Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Company in 2025

Figure 47. PET Diagnostic Radiopharmaceuticals Revenue by Company in 2025 (\$ millions)

Figure 48. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Company in 2025

Figure 49. Global PET Diagnostic Radiopharmaceuticals Sales Market Share by Geographic Region (2021-2026)

Figure 50. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share by Geographic Region in 2025

Figure 51. Americas PET Diagnostic Radiopharmaceuticals Sales 2021-2026 (K Dose)

Figure 52. Americas PET Diagnostic Radiopharmaceuticals Revenue 2021-2026 (\$

millions)

Figure 53. APAC PET Diagnostic Radiopharmaceuticals Sales 2021-2026 (K Dose)

Figure 54. APAC PET Diagnostic Radiopharmaceuticals Revenue 2021-2026 (\$ millions)

Figure 55. Europe PET Diagnostic Radiopharmaceuticals Sales 2021-2026 (K Dose)

Figure 56. Europe PET Diagnostic Radiopharmaceuticals Revenue 2021-2026 (\$ millions)

Figure 57. Middle East & Africa PET Diagnostic Radiopharmaceuticals Sales 2021-2026 (K Dose)

Figure 58. Middle East & Africa PET Diagnostic Radiopharmaceuticals Revenue 2021-2026 (\$ millions)

Figure 59. Americas PET Diagnostic Radiopharmaceuticals Sales Market Share by Country in 2025

Figure 60. Americas PET Diagnostic Radiopharmaceuticals Revenue Market Share by Country (2021-2026)

Figure 61. Americas PET Diagnostic Radiopharmaceuticals Sales Market Share by Radionuclide (2021-2026)

Figure 62. Americas PET Diagnostic Radiopharmaceuticals Sales Market Share by Application (2021-2026)

Figure 63. United States PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 64. Canada PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 65. Mexico PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 66. Brazil PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 67. APAC PET Diagnostic Radiopharmaceuticals Sales Market Share by Region in 2025

Figure 68. APAC PET Diagnostic Radiopharmaceuticals Revenue Market Share by Region (2021-2026)

Figure 69. APAC PET Diagnostic Radiopharmaceuticals Sales Market Share by Radionuclide (2021-2026)

Figure 70. APAC PET Diagnostic Radiopharmaceuticals Sales Market Share by Application (2021-2026)

Figure 71. China PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 72. Japan PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 73. South Korea PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 74. Southeast Asia PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 75. India PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 76. Australia PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 77. China Taiwan PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 78. Europe PET Diagnostic Radiopharmaceuticals Sales Market Share by Country in 2025

Figure 79. Europe PET Diagnostic Radiopharmaceuticals Revenue Market Share by Country (2021-2026)

Figure 80. Europe PET Diagnostic Radiopharmaceuticals Sales Market Share by Radionuclide (2021-2026)

Figure 81. Europe PET Diagnostic Radiopharmaceuticals Sales Market Share by Application (2021-2026)

Figure 82. Germany PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 83. France PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 84. UK PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 85. Italy PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 86. Russia PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 87. Middle East & Africa PET Diagnostic Radiopharmaceuticals Sales Market Share by Country (2021-2026)

Figure 88. Middle East & Africa PET Diagnostic Radiopharmaceuticals Sales Market Share by Radionuclide (2021-2026)

Figure 89. Middle East & Africa PET Diagnostic Radiopharmaceuticals Sales Market Share by Application (2021-2026)

Figure 90. Egypt PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 91. South Africa PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 92. Israel PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

millions)

Figure 93. Turkey PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 94. GCC Countries PET Diagnostic Radiopharmaceuticals Revenue Growth 2021-2026 (\$ millions)

Figure 95. Manufacturing Cost Structure Analysis of PET Diagnostic Radiopharmaceuticals in 2026

Figure 96. Manufacturing Process Analysis of PET Diagnostic Radiopharmaceuticals

Figure 97. Industry Chain Structure of PET Diagnostic Radiopharmaceuticals

Figure 98. Channels of Distribution

Figure 99. Global PET Diagnostic Radiopharmaceuticals Sales Market Forecast by Region (2027-2032)

Figure 100. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share Forecast by Region (2027-2032)

Figure 101. Global PET Diagnostic Radiopharmaceuticals Sales Market Share Forecast by Radionuclide (2027-2032)

Figure 102. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share Forecast by Radionuclide (2027-2032)

Figure 103. Global PET Diagnostic Radiopharmaceuticals Sales Market Share Forecast by Application (2027-2032)

Figure 104. Global PET Diagnostic Radiopharmaceuticals Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global PET Diagnostic Radiopharmaceuticals Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G5A0D35CA436EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5A0D35CA436EN.html>